Turn Therapeutics Inc. Common Stock Total Liabilities

Latest as of June 2026: $16.27 Million USD

Turn Therapeutics Inc. Common Stock total liabilities. Based on the latest financial reports, Turn Therapeutics Inc. Common Stock (TTRX) has total liabilities worth $16.27 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Turn Therapeutics Inc. Common Stock short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Total Liabilities of Turn Therapeutics Inc. Common Stock (2023–2025)

Total liabilities of Turn Therapeutics Inc. Common Stock from 2023 to 2025. This chart illustrates how Turn Therapeutics Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.

Turn Therapeutics Inc. Common Stock Competitors by Total Liabilities

The table below lists competitors of Turn Therapeutics Inc. Common Stock ranked by their total liabilities.

Company Country Total Liabilities
Panin Financial Tbk
JK:PNLF
Indonesia Rp174.93 Trillion
Clearview Wealth Ltd
AU:CVW
Australia AU$717.27 Million
Nanjing Chixia Development Co Ltd
SHG:600533
China CN¥14.53 Billion
BLS E-Services Limited
NSE:BLSE
India Rs-5.70 Billion
Jiangsu Holly Corp
SHG:600128
China CN¥3.51 Billion
Plum Acquisition Corp. IV Unit
NASDAQ:PLMKU
USA $7.35 Million
Holcim Argentina SA
BA:HARG
Argentina AR$433.18 Billion
Picpay Holdings Netherlands N.V. Class A Common Shares
NASDAQ:PICS
USA $45.79 Billion

Liability Composition Analysis (2023–2025)

This chart breaks down Turn Therapeutics Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Turn Therapeutics Inc. Common Stock.

Liquidity & Leverage Metrics

Turn Therapeutics Inc. Common Stock Total Liabilities Ratios Explained

Turn Therapeutics Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.19 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 23.69 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.96 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Turn Therapeutics Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Turn Therapeutics Inc. Common Stock (2023–2025)

The table below shows the annual total liabilities of Turn Therapeutics Inc. Common Stock from 2023 to 2025.

Year Total Liabilities Change
2025-12-31 $7.48 Million +235.78%
2024-12-31 $2.23 Million +15.49%
2023-12-31 $1.93 Million --

About Turn Therapeutics Inc. Common Stock

NASDAQ:TTRX USA Biotechnology
Market Cap
$288.80 Million
Market Cap Rank
#14702 Global
#3511 in USA
Share Price
$9.51
Change (1 day)
-1.45%
52-Week Range
$2.71 - $15.34
All Time High
$15.34
About

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and de… Read more